US 12,479,930 B2
Proteins specific for BAFF and B7RP1 and uses thereof
Hailing Hsu, Moorpark, CA (US); Ming Zhang, Thousand Oaks, CA (US); Gunasekaran Kannan, Daly City, CA (US); Frederick W. Jacobsen, Newbury Park, CA (US); and Wayne H. Tsuji, Seattle, WA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Sep. 28, 2022, as Appl. No. 17/936,062.
Application 17/936,062 is a continuation of application No. 16/579,321, filed on Sep. 23, 2019, granted, now 11,492,417.
Application 16/579,321 is a continuation of application No. 14/776,399, granted, now 10,421,823, issued on Sep. 24, 2019, previously published as PCT/US2014/024908, filed on Mar. 12, 2014.
Claims priority of provisional application 61/942,776, filed on Feb. 21, 2014.
Claims priority of provisional application 61/780,260, filed on Mar. 13, 2013.
Prior Publication US 2023/0128444 A1, Apr. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/46 (2006.01); A61K 39/395 (2006.01); A61P 19/02 (2006.01); A61P 29/02 (2006.01); A61P 37/06 (2006.01); C07K 16/18 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/468 (2013.01) [A61K 39/3955 (2013.01); A61P 19/02 (2018.01); A61P 29/02 (2018.01); A61P 37/06 (2018.01); C07K 16/18 (2013.01); C07K 16/241 (2013.01); C07K 16/2827 (2013.01); C07K 16/2875 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01)] 18 Claims
 
1. A bispecific protein that can bind B7RP1 and BAFF, wherein the bispecific protein comprises:
(a) an anti-B7RP1 antibody that comprises a light chain complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO:8, a light chain complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO:9, a light chain complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 10, a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 11, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 13; and
(b) at least one BAFF-binding peptide that is 10 to 40 amino acids long.